Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On May 6, 2025, MIRA Pharmaceuticals announced the successful completion of an FDA-required neurotoxicity study for its drug Ketamir-2, which showed no signs of brain toxicity. The study, conducted on Sprague-Dawley rats, demonstrated that Ketamir-2 did not cause neuropathologic changes, unlike the positive control MK-801, which showed evidence of neurotoxic lesions. These findings will be submitted to the FDA, potentially impacting MIRA’s regulatory progress and industry positioning by confirming the safety profile of Ketamir-2.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of novel oral NMDA receptor antagonists. The company is listed on NASDAQ under the ticker MIRA and is engaged in clinical development programs aimed at addressing neurotoxicity concerns associated with similar compounds.
Average Trading Volume: 1,185,430
Technical Sentiment Signal: Hold
See more data about MIRA stock on TipRanks’ Stock Analysis page.